152536-21-5

Basic information

• Product Name: 6-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-, Methyl ester
• Synonyms: 6-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-, Methyl ester;methyl 4-oxo-3,4-dihydroquinazoline-6-carboxylate
• CAS NO: 152536-21-5
• Molecular Formula: C10H8N2O3
• Molecular Weight: 204
• Mol File: 152536-21-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 400.4±47.0 °C(Predicted)
• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• PKA: 0.20±0.20(Predicted)
• CAS DataBase Reference: 6-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-, Methyl ester(152536-21-5)
• EPA Substance Registry System: 6-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-, Methyl ester(152536-21-5)

Safety Data

• Hazardous Substances Data: 152536-21-5(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 16064-08-7 6-iodo-4-hydroxyquinazoline 
• 6737-42-4 1,3-bis-(diphenylphosphino)propane 
• 33986-75-3 4-oxo-3,4-dihydroquinazoline-6-carboxylic acid 

Downstream Products

• 152536-17-9 methyl 4-chloroquinazoline-6-carboxylate 

Relevant articles and documents

HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS

The present invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; (I) which are inhibitors of WDR5. The present invention also provides pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additional therapeutic agent and the therapeutic uses of such compounds.

BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing thienopyrimidine or oxoquinazoline derivatives are disclosed of the general formula (1) or formula (2) where X is a linker and Y is an aromatic moiety or N(R5)(R6).

QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY

A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt: (I) wherein Rx represents a group represented by the formula(II): where R1 represents a hydrogen atom, an alkyl group which may be substituted or the like, Z represents -O-, -N(R10)- or the like, R10 represents a hydrogen atom, an alkyl group or the like, R2 represents a hydrogen atom, an alkyl group which may be substituted or the like, R18 represents a hydrogen atom, an alkyl group which may be substituted or the like, R19 represents an alkyl group which may be substituted or the like, W1 represents a non-aromatic nitrogenated heterocyclic group which may be substituted, and R17 represents a hydrogen atom, an alkyl group which may be substituted or the like; R3 and R4 independently represent a hydrogen atom, an alkyl group which may be substituted or the like; X represents -O-, -S-, -N(R12)- or the like; R12 represents a hydrogen atom, an alkyl group or the like; and A represents a phenyl group which may be substituted or the like. The compound can inhibit both EGF receptor tyrosine kinase and HER2 tyrosine kinase.